Evidence map›Paper›PMID 39179680›Full record

ArticleNeuromolecular medicine2024

Neuroprotective Effects of VGLUT1 Inhibition in HT22 Cells Overexpressing VGLUT1 Under Oxygen Glucose Deprivation Conditions.

B Pomierny, W Krzyżanowska, A Skórkowska, B Budziszewska, J Pera

Abstract read
In one paragraph

Article in Neuromolecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

B PomiernyDepartment of Toxicological Biochemistry, Jagiellonian University Medical College, Kraków, Poland. bartosz.pomierny@uj.edu.pl.ORCID 0000-0002-5352-5324
W KrzyżanowskaDepartment of Toxicological Biochemistry, Jagiellonian University Medical College, Kraków, Poland.
A SkórkowskaDepartment of Toxicological Biochemistry, Jagiellonian University Medical College, Kraków, Poland.
B BudziszewskaDepartment of Toxicological Biochemistry, Jagiellonian University Medical College, Kraków, Poland.
J PeraDepartment of Neurology, Jagiellonian University Medical College, Kraków, Poland. joanna.pera@uj.edu.pl.ORCID 0000-0001-6142-2969

Funding

Narodowe Centrum Nauki 2016/21/B/NZ4/03294
6 · The paper itself

Abstract

Glutamate (Glu) is a major excitatory neurotransmitter in the brain, essential for synaptic plasticity, neuronal activity, and memory formation. However, its dysregulation leads to excitotoxicity, implicated in neurodegenerative diseases and brain ischemia. Vesicular glutamate transporters (VGLUTs) regulate Glu loading into synaptic vesicles, crucial for maintaining optimal extracellular Glu levels. This study investigates the neuroprotective effects of VGLUT1 inhibition in HT22 cells overexpressing VGLUT1 under oxygen glucose deprivation (OGD) conditions. HT22 cells, a hippocampal neuron model, were transduced with lentiviral vectors to overexpress VGLUT1. Cells were subjected to OGD, with pre-incubation of Chicago Sky Blue 6B (CSB6B), an unspecific VGLUT inhibitor. Cell viability, lactate dehydrogenase (LDH) release, mitochondrial membrane potential, and hypoxia-related protein markers (PARP1, AIF, NLRP3) were assessed. Results indicated that VGLUT1 overexpression increased vulnerability to OGD, evidenced by higher LDH release and reduced cell viability. CSB6B treatment improved cell viability and reduced LDH release in OGD conditions, particularly at 0.1 μM and 1.0 μM concentrations. Moreover, CSB6B preserved mitochondrial membrane potential and decreased levels of PARP1, AIF, and NLRP3 proteins, suggesting neuroprotective effects through mitigating excitotoxicity. This study demonstrates that VGLUT1 inhibition could be a promising therapeutic strategy for ischemic brain injury, warranting further investigation into selective VGLUT1 inhibitors.

Indexed as

Cell HypoxiaCell SurvivalGlucoseHippocampusMembrane Potential, MitochondrialVesicular Glutamate Transport Protein 1AnimalsCell LineGlutamic AcidL-Lactate DehydrogenaseMiceNeuronsNeuroprotective AgentsOxygenVesicular Glutamate Transport Protein 2GlucoseGlutamic AcidL-Lactate DehydrogenaseNeuroprotective AgentsOxygenSlc17a6 protein, mouseSlc17a7 protein, mouseVesicular Glutamate Transport Protein 1Vesicular Glutamate Transport Protein 2Brain ischemiaChicago Sky Blue 6BGlutamateOxygen glucose deprivationVesicular glutamate transporters

Identifiers

PMID39179680
PMCPMC11343943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.